FDA Grants Fast Track Designation to Investigational Narcolepsy Treatment
The oral orexin 2 receptor agonist currently in phase 1b development for patients with narcolepsy.
The oral orexin 2 receptor agonist currently in phase 1b development for patients with narcolepsy.
'He was the most dedicated and dependable employee I have ever had the privilege of working with.'
The transition is expected to reduce professional fees and potentially impact procedure volume.
Following the establishment of new CMS reimbursement codes for digital mental health treatments, the funding will support the commercial expansion of two prescription products.
Physician-owned practices supported by Vivos in Nevada are now in-network with major commercial insurers and Medicare, expanding patient access to its sleep apnea treatments.
Tirzepatide copycats have implications for the safety of patients seeking treatment for obesity and obstructive sleep apnea.
The new center is part of a national expansion strategy using a capital-efficient affiliation model with existing sleep practices.
Survey data shows sleep lab leaders prioritize validation and certification when implementing sleep study autoscoring software.
Earn sleep continuing education credits (CSTEs) from Sleep Review's July/August 2025 digital edition.